FDBusiness.com

Nestlé Health Science to Develop New Therapy to Treat Ulcerative Colitis

 Breaking News
  • Sweets and Snacks New Product Development Thrives on Adventure and Bite-size Trends With one in four global consumers increasing their consumption of confectionery over the past year (Innova Market Insights Consumer Survey, 2018) because “there is more variety & novelty available,” the food industry is responding. New data from Innova Market Insights finds a 15 percent average annual growth in global confectionery launches with a “discovery” claim [...]...
  • 80,000 Tonnes of Skimmed Milk Powder Sold in Biggest Tender A total of 80,424.05 tonnes of the skimmed milk powder bought into public stock by the European Commission since 2015 were sold in the latest tender sale, bringing the remaining stock to around 22,000 tonnes out of the original 380,000 tonnes, stockpiled since the crisis that hit the dairy sector in 2015. In effect, almost [...]...
  • Müller Rolls Out ‘Stealth’ Milk Caps Müller, Britain’s leading producer of branded and private label fresh milk, cream, butter and ingredients, is rolling out a new lightweight recyclable milk cap, which uses 13% less plastic material. The innovative solution allows the business to remove 300 tonnes of plastic every year, the equivalent weight of 231 million ‘stealth’ milk caps. The dairy company has [...]...
  • Greene King Announces New Chief Executive The board of Greene King has announced that Nick Mackenzie will join the board on 1st May 2019 as chief executive in succession to Rooney Anand. Nick Mackenzie will be joining from Merlin Entertainments where, as a member of the executive committee, he is responsible for the Midway portfolio of attractions, which comprises over 100 [...]...
  • Irish Grocery Market Hits Festive Record as Retailers Cash in on Christmas The Irish grocery market grew by an impressive 3.0% over the 12 weeks to 30 December, ensuring a record festive period for retailers. The latest Kantar Worldpanel data shows value sales reached €995 million in the month of December – the highest monthly total ever recorded in the Irish grocery market. This was driven by [...]...

Nestlé Health Science to Develop New Therapy to Treat Ulcerative Colitis

Nestlé Health Science to Develop New Therapy to Treat Ulcerative Colitis
September 22
10:00 2015

Nestlé Health Science has entered into a license agreement with Lipid Therapeutics for exclusive rights worldwide, except for Europe and Australia, to Lipid Therapeutics’ LT-02 compound (phosphatidylcholine), a novel barrier function therapy for patients with mild-to-moderate ulcerative colitis. Under this agreement, Nestlé Health Science will further develop and commercialize LT-02 upon marketing approval by the relevant authorities in the licensed geographies. Nestlé Health Science plans to start phase III clinical trials in the US in 2016. The financial terms of the licensing partnership are not being disclosed.

Lipid Therapeutics’ European development partner, Dr Falk Pharma GmbH, a pharmaceutical company specialized in gastroenterology, announced the start of phase III trials for LT-02 in Europe in October 2014. As part of a strategic development approach, Nestlé Health Science, Dr Falk and Lipid Therapeutics will collaborate to generate the required clinical evidence in support of LT-02’s beneficial effects in the treatment of ulcerative colitis in order to obtain drug regulatory approvals.

More than one million people worldwide are estimated to suffer from ulcerative colitis, a chronic and debilitating inflammatory condition of the large intestine. The most common treatment is 5-aminosalicylic acid (mesalazine), However it is estimated that 40% of patients receiving the recommended dose of 5-aminosalicylic acid continue to experience persistent disease activity flares. The NHSc development program will primarily assess LT-02 as an add-on therapy to 5-aminosalicylic acid. LT-02 has a novel mode of action that restores the colonic barrier function in the gut mucosa or ‘wall’ and through anti-inflammatory signalling and represents a first-in-class therapy for those patients still suffering flares while being treated with mesalazine.

Greg Behar CEO of Nestlé Health Science, says: “LT-02 has paradigm changing potential in the management of ulcerative colitis in terms of improving patient outcomes and reducing the need for biologics and corticosteroids. The growing number of patients that suffer from chronic gastrointestinal conditions worldwide increases our determination to make an impact, through innovative, integrated therapeutic approaches. This agreement enables us to further build our gastrointestinal pipeline, a key focus of our Novel Therapeutic Nutrition business area with the aim of developing nutritional therapies coupled with innovative drug and diagnostics solutions.”

Dr Gerhard Keilhauer, CEO of Lipid Therapeutics, says: “Based upon initial trials, we are convinced of the transformational potential of LT-02. With Dr Falk Pharma and now Nestlé Health Science as licensees in key geographies, the resources and capabilities are at work to translate potential into a breakthrough therapy.”

This licensing agreement is part of Nestlé Health Science’s strategy to develop its product portfolio for gastrointestinal diseases, a key focus of its Novel Therapeutic Nutrition business area.

About Author

mike

mike

Related Articles



Food & Drink Business Conference & Exhibition 2016

Upcoming Events

  • June 18, 2019Multimodal 2019
AEC v1.0.4

find food jobs

The Magazine

F&D Business Preferred Suppliers

New Subscriber

Subscribe Here



Advertisements